Omeros Corp. said it agreed to settle a patent infringement lawsuit against India's Lupin Ltd regarding a generic version of its eye drug Omidria.
Lupin had filed an application with the U.S. Food and Drug Administration to market a generic version of Omidria in 2017.
Under the settlement, Lupin confirmed the validity of all asserted patents for Omidria, with Oct. 23, 2033 as the last date for the expiration of Omeros' asserted patents.
The terms regarding the market entry of the generic version were similar to Omeros' previous settlement with Endo International PLC, under which a generic cannot be launched before April 1, 2032.
Seattle-based Omeros develops and sells drugs that target inflammation, bleeding disorders and central nervous system disorders.
